Recently it was shown that several new pseudotyped adenoassociated virus (AAV) vectors support cardioselective expression of transgenes. The molecular mechanisms underlying this propensity for cardiac cell transduction are not well understood. We comparatively analyzed AAV vector attachment, internalization, intracellular trafficking, and nuclear uncoating of recombinant self-complementary (sc) AAV2.2 versus pseudotyped scAAV2.6 vectors expressing green fluorescence protein (GFP) in cells of cardiac origin. In cardiac-derived HL-1 cells and primary neonatal rat cardiomyocytes (PNCMs), expression of GFP increased rapidly after incubation with scAAV2.6-GFP, but remained low after scAAV2.2-GFP. Internalization of scAAV2.6-GFP was more efficient than that of scAAV2.2-GFP. Nuclear translocation was similarly efficient for both, but differential nuclear uncoating rates emerged as a key additional determinant of transduction: 30% of all scAAV2.6-GFP genomes translocated to the nucleus became uncoated within 48 h, but only 16% of scAAV2.2-GFP genomes. In contrast to this situation in cells of cardiac origin, scAAV2.2-GFP displayed more efficient internalization and similar (tumor cell line HeLa) or higher (human microvascular endothelial cell (HMEC)) uncoating rates than scAAV.2.6-GFP in non-cardiac cell types. In summary, both internalization and nuclear uncoating are key determinants of cardiac transduction by scAAV2.6 vectors. Any in vitro screening for the AAV pseudotype most suitable for cardiac gene therapy -which is desirable since it may allow significant reductions in vector load in upcoming clinical trials -needs to quantitate both key steps in transduction.
Introduction
Adeno-associated virus (AAV) vectors are rapidly evolving tools for therapeutic gene transfer into different target organs. In recent years, they have also been employed for therapeutic gene transfer into the myocardium in several animal models of human cardiovascular diseases. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] Recent reports have shown that pseudotyping of AAV vectors as well as artificial capsid modifications 13 significantly alter their transgene targeting in vivo. Different AAV pseudotypes [14] [15] [16] [17] [18] [19] [20] [21] have different receptorbinding sites in their capsids, providing a possible molecular basis to explain their differential tissue targeting. For only few AAV subtypes, however, the cellular receptor complements mediating cellular attachment and internalization are known so far [21] [22] [23] and therefore, the extent by which AAV targeting is determined at the receptor level could not yet be fully elucidated. Numerous other structures and processes influence the transduction efficacy of vectors, for example barriers such as the vascular endothelium may a priori prevent vector access to their target cells even if they express the appropriate receptors. 24 Beyond the receptor level, the intracellular trafficking of AAV vectors has recently found increasing interest as an important determinant of AAV transduction efficacy. 22, [25] [26] [27] Nuclear translocation of AAV particles via early and late endosomes was rather inefficient for prototype AAV2 vectors in vitro, 28 and was highly variable between AAV pseudotypes. Even after the arrival of AAV particles in the nucleus, their genome is not readily available to support transgene expression. One possible intranuclear limitation for single-stranded 'monomeric' AAV vectors is their requirement for second-strand synthesis before transgene expression can start, 29 whereas this limitation does not exist for self-complementary 'dimeric' AAV vectors (scAAVs), 30 as used in the current study. A possible limitation of both monomeric and dimeric vectors is the uncoating of AAV capsids in the nucleus, the efficiency of which varies greatly between pseudotypes in the liver in vivo 27 and, for example, prevents efficient transduction of mouse primary hematopoietic cells in vitro. 31 We investigated the transduction mechanisms of two dimeric scAAV vectors in cells of cardiac and non-cardiac origin, since adeno-associated virus 2.6 (AAV2.6) pseudotypes showed far more efficient transduction of mouse hearts in vivo than the prototype adeno-associated virus 2.2 (AAV2.2) vectors. 32, 33 Previous reports have demonstrated the superiority of AAV2.6 and AAV2.8 34 pseudotypes in transducing hearts in vivo by analyzing the resulting transgenic green fluorescence protein (GFP) expression in different organs after intravenous injection. We studied all AAV transduction steps from cellular attachment to nuclear uncoating for dimeric scAAV2.2 as compared to pseudotyped scAAV2.6 in cardiac and non-cardiac cells. Beyond the cell surface virus receptor level, which determines the efficacy of attachment and internalization of AAV particles, we observed differential nuclear uncoating of the vectors as a second significant determinant of their transduction rates in the respective cells.
Results
Cell type-specific transduction rates of scAAV2.2 and scAAV2.6
To compare the efficacies of transgene expression ('transduction rates') of scAAV2.2 and scAAV2.6 in cells of cardiac origin, we developed two recombinant AAV vectors by packaging a recombinant scAAV2 genome encoding the Renilla GFP cDNA under the control of a cytomegalovirus (CMV) promotor, either into an AAV2 (scAAV2.2-GFP) or an AAV6 capsid (scAAV2.6-GFP). Two cell types of cardiac origin (the HL-1 cell line and primary neonatal rat cardiomyocytes, PNCMs) and two noncardiac cell lines (tumor cell line HeLa and human microvascular endothelial cell (HMEC)) were then incubated with scAAV2.2-GFP or scAAV2.6-GFP at a dose of 2 Â 10 3 vector genomes per cell (vg/c). The cells were analyzed for GFP expression 24, 48, and 72 h after incubation by using fluorescence microscopy and fluorescence-activated cell sorting (FACS). In PNCMs and HL-1 cells, the fraction of GFP-positive cells increased steadily to 35 and 25%, respectively, 72 h after scAAV2.6-GFP incubation, whereas with scAAV2.2-GFP vector it remained 6.3-fold (HL-1) and 7.0-fold (PNCMs) lower. Among the non-cardiac cells, HMECs showed slightly higher transgene expression of 32% with scAAV2.6-GFP as compared to 20% with scAAV2.2-GFP. In contrast, HeLa cells not only showed the highest overall transgene expression rate, but also an inverse situation with lower transgene expression after incubation with scAAV2.6-GFP (60% GFP-positive cells) than after scAAV2.2-GFP (88% positive cells) (Figures 1a and b ). These results demonstrate that the transduction rate of scAAV2.6-GFP vector is clearly superior to that of scAAV2.2-GFP in cells of cardiac origin.
Attachment and internalization of scAAV2.2 and scAAV2.6
To clarify the molecular basis for these different transduction rates, we examined the transductional pathway from the uptake and nuclear trafficking of the virion to the uncoating of the vector genomes within the nucleus. To first assess the extent by which cellular uptake mechanisms determine the cell type-specific transduction rates, the cell surface attachment and the internalization of scAAV2.2-GFP and scAAV2.6-GFP virions to the four cell types were determined. HL-1, HeLa, HMECs, and PNCMs were seeded and grown overnight, then stored on ice, and after removal of the culture medium incubated with 2 Â 10 3 vg/c of either vector. After further incubation on ice for only 15 min and subsequent washing to remove non-adsorbed AAV, total DNA was isolated from the cultured cells and analyzed by Southern blot hybridization. The levels of attached scAAV2.2-GFP were higher than that of scAAV2.6-GFP in all investigated cell lines, so that they do not correlate with the observed higher transduction rate of scAAV2.6-GFP in cardiac cells (Figure 2 ). To investigate now the vector internalization rates, cells were incubated with scAAV2.2-GFP or scAAV2.6-GFP for a longer period of 2 h at 371C. Total DNA was then isolated from the cells either without further treatment, or after trypsinization of the cells to cleave off any noninternalized but attached vector particles. Internalization was 3.2-fold higher in HL-1 and 4.0-fold higher in PNCMs for scAAV2.6-GFP (Figures 3a and b) . In HMECs and HeLa cells, a reverse situation was observed. Internalization was 3.2-fold higher in HeLa and 2.3-fold higher in HMECs treated with scAAV2.2-GFP. These results indicate that differential internalization efficacy is an important factor that determines the higher transduction rate of cardiac-derived cells by scAAV2.6-GFP. However, the differences in the efficacy of scAAV vector uptake into the cells obviously explain only part of the observed differences in transduction, as shown in Figures 1a and b. As a rough estimate, a 7.0-fold higher transduction of PNCMs by scAAV2.6-GFP was observed as compared to only 4.0-fold higher internalization rate. A 6.3-fold higher transduction of HL-1 cells by scAAV2.6-GFP was observed as compared to only 3.2-fold more efficient internalization rate. On the other hand, the 2.4-fold higher internalization rate of scAAV2.2-GFP in HMECs does not translate into a higher transduction rate, which is unexpectedly higher for scAAV2.6-GFP. The 3.1-fold higher internalization of scAAV2.2-GFP in HeLa was observed as compared to only 1.4-fold higher transduction. Obviously, there were additional determinants of transduction beyond the cell surface receptor level.
Nuclear translocation of scAAV2.2 and scAAV2.6
As the next step in the AAV transductional pathway, we analyzed the intracellular trafficking of the two vectors. The four cell lines were incubated with scAAV2.2-GFP or scAAV2.6-GFP, and the nuclear and cytoplasmic fractions were then isolated 48 h after transduction. Low molecular weight DNA isolated from each fraction was then submitted to slot blot analysis. Across all cell types investigated, 70-90% of the internalized vector genomes detectable within the cells were translocated to the nuclear fraction 48 h after transduction (Figure 4 ). Only slight differences were observed in the trafficking behavior of the two vector serotypes. In no case more than 1.3-fold differences were observed when the fraction of nucleartranslocated vector genome was measured for both serotypes in each of the four cell types. This finding showed that there were no cell type-specific differences in nuclear translocation rates between scAAV2.2-GFP and scAAV2.6-GFP. Therefore, nuclear trafficking does not seem to be an important factor in determining the different transduction rates by scAAV2.2-GFP and scAAV2.6-GFP of the cell types investigated.
Cell type-specific nuclear uncoating of scAAV2.2 and scAAV2.6
As last step, we comparatively analyzed the nuclear uncoating rates of scAAV2.2-GFP and scAAV2.6-GFP in the four cell types. The nuclear fractions isolated from the cells 48 h after transduction with either vector were examined for the presence of uncoated vector genome by filtering through low binding regenerated cellulose which retains the virions, whereas any uncoated 'free' vector DNA in solution flows through the filter. Low molecular weight DNA was isolated from both the filtrate and the retentate of each sample and then submitted to slot blot analysis. As shown in Figure 5a , the fractions of viral genome detected in the filtrates were low as compared to those detected in the retentates. 
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As shown in Figure 5b , however, the highest uncoating rates were observed in cells of cardiac origin (HL-1, PNCMs) transduced with scAAV2.6-GFP. The uncoating rate for this vector type was 33% in HL-1 cells and 30% in PNCMs, respectively. In contrast, only 16% of scAAV2.2-GFP virions in the nuclear fraction was uncoated, correlating well with the different transduction rates of the two vector types. Opposite results were obtained in HMECs where a far greater fraction of uncoated scAAV2.2-GFP (30%) than scAAV2.6-GFP (17%) was observed. In HeLa cells that show the highest transduction rates with both AAV vector types (Figures 1a and b) , the nuclear uncoating rate was similar for scAAV2.2-GFP (19%) and scAAV2.6-GFP (21%), but lower than in the other cell types. The results obtained after filtration could also be confirmed by DNAse I digestion of the nuclear fraction and subsequent slot blot analysis. Moreover, a 72 h time course investigation in PNCMs revealed rapid uncoating of scAAV2.6-GFP, whereas the uncoating of Figure 2 Cellular attachment of scAAV2.2-GFP versus scAAV2.6-GFP vectors. Cells were transduced with 2 Â 10 3 vg/c of scAAV2.2-GFP or scAAV2.6-GFP, respectively. Low molecular weight DNA was isolated from the cells after incubation at 01C for 15 min and the AAV DNA load was then analyzed from 5 mg of total DNA by Southern blot with vector DNA-specific probes. The quantity of AAV genome attached was higher for scAAV2 than scAAV6 across all four cell types. The two upper bands (SC) probably correspond to double-stranded (ds) and single-stranded (ss) scAAV genomes, the lower band to single-stranded monomeric (sm) genome. GFP, green fluorescence protein. 2-GFP or scAAV2.6-GFP. After 2 h, the cells were either trypsinized to remove extracellular-bound particles, or left untrypsinized. The total DNA was then isolated from the cells and 4 mg of DNA was subjected to slot blot analysis using a vector-specific probe. As a control, 4 mg of genomic DNA from each cell type without any vector were used. The experiment was carried out two times with similar results. (b) For the determination of internalized scAAV2.2-GFP and scAAV2.6-GFP vector particles, the signal intensities in slot blots (a) were densitometrically quantified. The vector particles in each sample were calculated using SmaI-digested AAV genome standard (not shown) obtained by digestion of the plasmid pscAAV-GFP; GFP; green fluorescence protein.
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I Sipo et al scAAV2.2-GFP was distinctly delayed in cardiac cells (Figure 5c ). In summary, these data show that the uncoating process after nuclear translocation of different AAV virion types may be very slow in 'inappropriate' cell types. Nuclear uncoating is a well-known key step in the AAV transduction process and obviously explains part of the differential cell type-specific transduction rates of scAAV2.2-GFP and scAAV2.6-GFP in studies on both cell types of cardiac origin.
Discussion
Recombinant AAV vectors have rapidly evolved as tools for the genetic therapy of various human disorders. For numerous target diseases, they offer advantages over other viral vector systems such as adenoviral vectors, which are less stable and more immunogenic in vivo. AAV vectors have already been employed for therapeutic gene transfer into the myocardium in several animal models of human cardiovascular diseases. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] Multiple AAV serotypes have been isolated in recent years which show grossly different tissue and organ tropisms. [14] [15] [16] [17] [18] [19] [20] This may be due to different cellular receptor affinities of the respective AAV virions, but for only few of the currently known AAV types the cellular receptors are currently known. 14, 22, 23, 35 The choice of AAV serotype and the optimal design of the AAV vector for a given therapeutic purpose also remain challenging because the molecular mechanisms beyond the receptor level, which determine their different potential to support transgene expression in various cell types, are incompletely understood. One well-documented factor limiting AAV-based transgene expression is the second-strand synthesis after infection with monomeric AAV vector. 36, 37 To exclude the influence of this step, in our studies we used only scAAV vectors, which are more efficient than single-stranded monomeric vectors. 30, 38 Common steps in the transduction process of host cells by any AAV vector are its attachment to the cell surface, internalization into the cell by endocytosis, intracellular trafficking through the endosomal compartment, endosomal escape, and import into the nucleus where uncoating of the viral genome ensues. In the case of sc vectors this is immediately followed by transgene expression, whereas monomeric vectors first have to accomplish second-strand synthesis. The exact molecular mechanisms governing most steps seem to be unique to individual AAV serotypes and to depend on their capsid protein structures. 22 The current study has comparatively analyzed the sequential transduction steps for the two specific vectors scAAV2.2-GFP and the related pseudotype vector scAAV2.6-GFP. We found cell typedependent differential transgene expression (transduction rates) by these vectors, in accordance with others who have shown that AAV6 is more efficient in transducing myocytes than AAV2. 34, 39, 40 Since the vectors scAAV2.2-GFP and scAAV2.6-GFP that we employed carry identical sc genomes derived from AAV2, the nature of their AAV2-or AAV6-derived capsid proteins is obviously responsible for any differences observed.
Viral receptors at the target cell surface play a key role in the transduction process since they represent the first biological barrier to be overcome during viral infection. AAV enters the cells by first binding to a primary attachment receptor. 22 Our data showed generally lower cellular binding of scAAV2.6 as compared to scAAV2.2, to cardiac and non-cardiac cells as well. This may reflect the use of different attachment receptors by AAV2 and AAV6. 23, [41] [42] [43] Lower binding of AAV6 as compared to AAV2 were then due to lower AAV6 receptor densities at the cell surface, differences in their accessibility, or different virion-binding affinities. Importantly, however, the attachment data did not correlate with the differential transduction rates of cardiac and non-cardiac cells by scAAV2.2 and scAAV2.6. This suggests that the process of virus attachment is not of distinctive importance for scAAV2.6-specific transduction of cardiac cells.
The next step in the cellular uptake process is AAV internalization, which is a very rapid process 44 mediated by AAV receptors and co-receptors. Although several AAV2 receptors are identified 41, 45, 46 and the intracellular small GTP-binding protein Rac1 is known to be an important cofactor for the initiation of AAV2 endocytosis, 47 far less is known about AAV6 receptors and internalization mechanisms. 42, 23 We observed distinctly higher internalization rates for scAAV2.6 as compared to scAAV2.2 in cardiac cells. Given the inverse situation in non-cardiac cells, this suggests interaction of scAAV2.2 and scAAV2.6 with two distinct receptor/co-receptor systems differentially expressed on cardiac and noncardiac cell types. The internalization rates correlated well with the AAV serotype-specific transduction rates. Inefficient internalization, therefore, seems to be one key determinant for inefficient transduction of cardiac cells Differential nuclear uncoating of AAV pseudotype vectors I Sipo et al by AAV2. However, overall comparison of viral transduction, attachment, and internalization rates makes clear that only part of the gross differences in cardiac cell transduction by scAAV2.2 versus scAAV2.6 can be explained by different efficacies of the cellular surface receptor systems. Obviously, there exists at least one further determinant beyond the receptor level.
With respect to subsequent steps in the transduction process, we examined the nuclear translocation rate of internalized vectors as a potential source of cell-specific differences in transduction. We found, however, that for both scAAV2.2 and scAAV2.6 70-90% of the internalized vector genomes became translocated to the nucleus after 48 h and that these slight differences were unable to make a significant contribution to transduction rates. The data are in accordance with another study, 48 which found that in HeLa cells up to 70% of the vector genomes were translocated to the nucleus after this time. In contrast, a significant fraction of AAV vectors failed to enter the nucleus in other cell types such as NIH 3T3 fibroblasts 31 and murine hematopoietic cells. 31 The molecular details of trafficking of AAV vectors from the cell surface to the nucleus are not well understood, but modulation of endocytic processing enhanced the transduction rate of murine fibroblasts. 49 Furthermore, intact AAV particles are known to interact with FKBP52 and with dynein, which is involved in intracellular AAV transport to the nucleus. 26 A cellular serine/threonine protein phosphatase has also been shown to influence transduction efficacy. 50 Although disturbed intracellular transport and nuclear import obviously play a role in limiting AAV transduction of certain cell types, our data show that this is not the case for the cell types investigated here. The transduction rate in HeLa cells was 80% for scAAV2.2, whereas in both HL-1 cells and PNCMs it was below 5% for this vector type.
Having thus determined that the receptor level explains only part of the differential transduction and that nuclear vector translocation and of course the requirement for second-strand synthesis made no contribution, the nuclear uncoating remained as another possible source of variation. Uncoating of AAV occurs within the nucleus 44, 51 and leads to the release of the viral DNA. Therefore, the uncoating represents a key step in 2-GFP and scAAV2.6-GFP vectors for 2 h. Thereafter, they were washed and supplemented with fresh culture media. At 48 h after incubation, the nuclear fractions isolated from the cells were filtrated through a regenerated cellulose membrane filter. Low molecular weight DNA was isolated from the retentates and filtrates, and analyzed for AAV DNA. Viral DNA in the filtrates was considered as uncoated since coated AAV particles were retained in the retentates. Vector control: for control of complete retention of intact AAV particles by the membrane filter, scAAV2.2-GFP and scAAV2.6-GFP particles (4 Â 10 8 ) were mixed with 100 ml of the nuclear fraction isolated from non-transduced HeLa cells, respectively, and fractionated through the membrane filter, as described above. As shown, the AAV genomes were only detectable in the retentates indicating that AAV particles were completely retained by the membrane. The last line represents hybridization bands of AAV DNA isolated from the indicated amounts of AAV particles. (b) Quantification of uncoated AAV particles: the diagram illustrates the quantification of signal intensities from three separate slot blots performed, as indicated above (a). The percentage of uncoated AAV genome was calculated as the ratio of viral DNA load in the filtrate to the total DNA in the loaded nuclear fraction (retentates+filtrates) and multiplied by 100. The diagram represents the mean values of two separate experiments, values are given as means7s.d. Asterisks indicate significant differences (Po0.05). (c) Analysis of uncoating in PNCMs and HL-1 cells by DNase I digestion: The nuclear fractions isolated from both cell types were treated with DNase I for 4 h to digest uncoated DNA or were left untreated. Low molecular weight DNA was then isolated from each sample and analyzed for AAV DNA load by slot blot analysis. As DNase I digestion control, 100 ng of SmaI-digested pscAAV-GFP plasmid was mixed with 5 mg of cellular DNA. The last line shows hybridization bands of DNAs isolated from the indicated amounts of scAAV2.2-GFP vector (upper part of c). Additionally, the nuclear fractions isolated from PNCMs 24, 48 and 72 h after transduction with 10 3 or 2 Â 10 3 vg/c of scAAV2.6-GFP were treated with DNase I for 4 h or were left untreated and analyzed for AAV DNA by slot blot hybridization. A digestion control is also included in this middle part of (c). The lower part of (c) shows two histograms of the quantities of vector genome uncoated after the indicated times (at a dose of 10 3 vg/c on the left and 2 Â 10 3 vg/c on the right). GFP, green fluorescence protein.
Differential nuclear uncoating of AAV pseudotype vectors I Sipo et al the infectious process of AAV. In fact, we observed a correlation between the efficiency of scAAV2.2 and scAAV2.6 transduction and the nuclear uncoating rate in cells of cardiac origin. scAAV2.6-GFP yielded a rapidly rising transduction rate reaching 35% in PNCMs and 25% in HL-1 cells after 72 h, whereas the transduction yield of scAAV2.2-GFP remained below 5% over the whole time period. This is remarkable and suggests a direct causal relation to the respective nuclear uncoating rates since the quantity of vector genomes in the nucleus was about 70% for both vectors and across all cell types. Moreover, in line with these observations, we found distinct delayed scAAV2.2 uncoating in PNCMs during the investigation period. We, therefore, think that an important limitation of cardiomyocyte transduction by the AAV2 serotype arises from impaired uncoating of AAV2 virions in the nucleus. At least in the cardiac cell types investigated, this constitutes an important additional determinant of transduction beyond the cell surface receptor level.
The relative contributions of this nuclear uncoating and the other upstream steps to myocardial transduction in vivo need to be further investigated. The currently available experimental in vivo data 34 do not yet allow to distinguish between receptor-dependent and uncoatingdependent differences in the heart. However, for the liver it has already been clearly shown in vivo that rapid uncoating is essential for efficient liver transduction with Differential nuclear uncoating of AAV pseudotype vectors I Sipo et al pseudotyped AAV vectors. 27 Uncoating is a key determinant of in vivo transduction by AAV vectors at least in the liver, and our data suggest that this is also the case in the heart. Recently, very high cardiac transduction rates in vivo have been reported for the new serotype AAV9, which far exceeds that of AAV2 and also that of AAV6. [52] [53] [54] Currently, it is not clear which factors are responsible for the excellent in vivo performance of AAV9 -high virion stability in the circulation and ability to permeate the vascular endothelium have been discussed. 52 So far no comparative data on the cellular uptake, intracellular trafficking, and nuclear uncoating of AAV9 versus AAV6 and other serotypes are available.
In summary, the present study shows for four cell types of cardiac and non-cardiac origin that both AAV virion internalization and nuclear uncoating of the AAV genome, but not the trafficking of virions to the nucleus, are key determinants of transduction in vitro. The nuclear uncoating rate of AAV virions is cell type-and virion typedependent, constitutes a second important step in transduction beyond the receptor level, and underlies the low efficacy of scAAV2.2 in primary cardiomyocytes and the cardiac-derived HL-1 cell line. In contrast, the rapidly uncoating scAAV2.6 supported a rapid and continuous increase of transgene expression in these cells. Since the genomes were identical in both vector types, the differential uncoating is obviously due to specific capsid properties. We conclude that any in vitro screening for the AAV pseudotype most suitable for cardiac gene therapywhich is desirable since it may allow significant reductions in vector load in upcoming clinical trials -needs to quantitate both key steps in transduction.
Materials and methods
Cell cultures
HeLa (human cervix carcinoma) and HEK 293T (human embryonal kidney) cells were cultured in Dulbecco's Modified Eagle's Medium (Gibco BRL, Eggenstein, Germany). HMEC was cultured in endothelial cell growth medium MV (PromoCell, Heidelberg, Germany). HL-1 is a cardiac muscle cell line derived from the AT-1 mouse atrial cardiomyocyte tumor lineage. The cells can be serially passaged, yet they maintain the ability to contract and retain differentiated cardiac morphological, biochemical, and electrophysiological properties (Claycomb et al. 1998, Proc Natl Acad Sci USA, 2979-2984). HL-1 cells were a kind gift of WC Claycomb (LSU Health Center, New Orleans, USA) and cultured in Claycomb medium (JRH Biosciences, Lenexa, KS, USA). PNCMs were isolated from neonatal rat and cultured in CMRL 1415 Medium (Biochrom, Berlin, Germany) supplemented with 2.8 mM glucose, 5.4 mM KCl, 1.26 mM CaCl 2 , and 2 mM 5 0 -fluoro-2 0 -deoxyuridin (Sigma, Munich, Germany) as described. All media were supplemented with 10% fetal calf serum (FCS) and 1% each of penicillin and streptomycin.
Plasmid constructions
For the generation of sc 'dimeric' scAAV2.2-GFP and scAAV2.6-GFP vectors, a basic plasmid pscAAV-GFP with deletion of the terminal resolution site and the D-sequence at the 3 0 -ITR of the AAV genome (nucleotide positions 114-141) was constructed as follows: plasmid pAAV-MCS (Stratagene, La Jolla, CA, USA) was digested with HincII and MscI and the 2832 bp and 1234 bp fragments were harvested. The 2832-bp fragment was dephosphorylized and ligated to the 1234-bp fragment, thus generating a basic plasmid pscAAV. For construction of the GFP expression cassette, 0.5 kb of the b-globin intron sequence was removed from the plasmid pAAVhrGFP (Stratagene) by digesting this plasmid with SacII and ClaI. After fill-in of 5 0 -overhangs with T4-polymerase, the plasmid was re-ligated giving rise to the plasmid pAAV-GFP. The fragment containing the CMV promotor and the GFP cDNA was removed from pAAV-GFP after NdeI/BglII digestion and ligated in the NdeI/BamHIdigested pCMV-MCS (Stratagene) to generate the plasmid pCMV-GFP, since both BglII and BamHI yield compatible ends. A fragment containing the human U6 promotor was amplified from the pSilencer 2.1-U6 neo expression vector (Ambion, Huntingdon, UK) using the primer pair (gag aga tct atg aat tcc cca gtg gaa ag/agg cga tta agt tgg gta) and ligated in BglII/HindII-digested pCMV-GFP giving rise to the plasmid pCMV-GFP-R2. The bovine growth hormone polyadenylation signal sequences (bGH p(A)) were harvested by NheI/XbaIdigesting pAd5TRE-Luc 55 and ligated in the XbaIdigested and dephosphorylated pCMV-GFP-R2 to yield the plasmid pCMV-GFP-R2. After digestion of plasmid pCMV-GFP-R2 with MluI and BglII, the CMV-GFP-R2 fragment was harvested and finally ligated into BamHI/ MluI-digested pscAAV giving rise to the final construct pscAAV-GFP.
AAV vector development
scAAV2.2-GFP and pseudotyped scAAV2.6-GFP vectors were generated by co-transfection of vector plasmid with the respective packaging plasmid. For the production of scAAV2.2-GFP, pscAAV-GFP was co-transfected into HEK 293T cells with the plasmid pDG, which carries the AAV2 rep and cap genes, as well as Ad helper genes required for rAAV2 replication and packaging. For scAAV2.6-GFP, the same plasmid pscAAV-GFP was also co-transfected into HEK 293T with plasmid pDP6rs, a packaging plasmid carrying the AAV2 rep and AAV6 cap genes as well the Ad helper genes. The transfection was carried out as follows: 293T cells were split (7.5 Â 10 6 cells/14.5 cm cell culture plate) the day before the experiment, so that when transfected the cell confluence was about 75-80%. Twenty plates were used in five batches (five plates for one batch) for the transfection. To prepare CaPO 4 precipitates, 90 mg of vector plasmid pscAAV-GFP (18 mg/plate) was mixed with 270 mg of packaging plasmid (pDG or pDP6-rs) in a total volume of 5 ml of 0.25 M CaCl 2 solution. Then, 5 ml of 2 Â HBS pH 7.05 was added dropwise to the DNA-CaCl 2 solution and incubated at room temperature for 1 min. The transfection mixture (DNA-CaCl 2 -HBS) (2 ml) was transferred dropwise to each plate and cells were incubated at 371C for 48 h. At 48 h after transfection, cells were harvested after scraping from the 20 culture plates and centrifuged at 3000 r.p.m. in a centrifuge 5810 R (Eppendorf, Hamburg, Germany) for 10 min. The cell pellets were washed three times with phosphate-buffered saline (PBS). Cells were resuspended in 20 ml PBS solution supplemented with 0.5% desoxycholate. Benzonase (Nycomed Pharma, Roskilde, Denmark, pure grade) was added to the mixture (100 U/ml, final concentration) using a syringe equipped with a 200 Â 170 mm Luer Lock needle (Helwig, Berlin, Germany). Tubes were sealed and centrifuged in a Type 70 Ti rotor (Beckman) at 50 000 r.p.m. for 2 h 30 min at 181C. About 4 ml of the clear 40% step was aspirated after puncturing the tubes on the side with a syringe equipped with an 18-gauge needle. Vector titers were determined by using slot blot.
Isolation of nuclear and cytoplasmic fractions
Nuclear and cytoplasmic fractions from cells studied were isolated, as described. 49, 57, 58 Briefly, cells seeded on six-well plates were mock infected or infected with the recombinant scAAV2.2-GFP or scAAV2.6-GFP vector. At 48 h post-transduction, the cells were washed twice with PBS and detached from the culture dishes by trypsination. After centrifugation at 1200 r.p.m. in a centrifuge 5810 R (Eppendorf), the cell pellets were gently resuspended in 400 ml of hypotonic buffer (10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid pH 7.9. 1.5 mM MgCl 2 , 10 mM KCl, 0.5 mM dithiothreitol (DTT), 0.5 mM phenylmethylsulfonyl fluoride (PMSF) and incubated on ice for 5 min, after which 20 ml of 10% Nonidet P-40 (NP-40) was added to each tube. The samples were then mixed gently and centrifuged for 5 min at 500 r.p.m. at 41C. The supernatants (cytoplasmic fraction) were decanted and the pellets (nuclear fractions) were washed twice with 1 ml of hypotonic buffer. Both fractions were then stored at À201C for further use.
Isolation of low molecular weight DNA
Cell fractions were resuspended in 500 ml of hypotonic solution or extraction buffer (10 mM Tris-HCl pH 7.5, 10 mM MgCl 2 and 0.5% sodium desoxycholate) and were supplemented with 1% SDS and incubated at 371C for 30 min. Proteinase K (Roche, Basel, Switzerland) was then added to a final concentration of 40 mg/ml. After the proteinase K digestion was carried out at 371C for 2 h, NaCl was then added to a final concentration of 1.1 M and the digested samples were incubated overnight at 41C followed by centrifugation at 13 000 r.p.m. for 30 min at 41C. The supernatant was collected, extracted with phenol-chloroform, and DNA was ethanol precipitated before being resuspended in distilled water.
Southern blot analysis of AAV vector DNA
Cells were harvested at the indicated time point after transduction and the total DNA were isolated from the cells using the E.Z.N.A. Tissue DNA Mini Kit (Peqlab, Erlanger, Germany). Genomic/vector DNA mix (10 mg) was electrophoretically fractionated on a 1% agarose gel. The gel was then incubated in a denaturing solution (1.5 M NaCl, 0.5 M NaOH) for 1 h followed by neutralization in Tris-HCl (pH 8) buffer containing 1.5 M NaCl for 1 h. After transfer to a Hybond N nylon membrane (Amersham, Piscataway, NJ, USA), the membranes were hybridized with ( 32 P)dCTP-labeled 600 nt ss-antisense and 800 nt ss-sense CMV-GFP-specific DNA probes. The labeling of ss-antisense and ss-sense GFP-DNA probes was carried out in a PCR-like reaction as described. 23 using a CMVGFP-DNA fragment harvested after NotI digestion of pdsAAV-GFP as template. The hybridization signal intensity was determined and quantified by phosphoimaging in a Fuji Film BAS-1500.
Isolation of uncoated viral DNA and slot blot analysis
To analyze the nuclear uncoating of AAV virions, cells were seeded on six-well plates and allowed to grow overnight. The cells were then transduced with 2000 vg/ c of the indicated vector, and the nuclear and cytoplasmic fractions were isolated from three pooled wells, as described above. The nuclear fraction was resuspended in buffer containing 10 mM Tris-HCl (pH 7.5), 10 mM MgCl 2 , and 0.5% sodium desoxycholate and incubated for 1 h at 371C. Then, 100 ml of each nuclear fraction was transferred into a Amicon Ultra-4 1 000 000 MW centrifugal filter tube (Millipore, Billerica, MA, USA) and centrifuged at 3000 r.p.m. in a centrifuge 5810 R (Eppendorf) for 2 min. The same buffer (100 ml)was then added to the tubes and again centrifuged. This step was repeated three times after which retentates (resuspended in 500 ml buffer) and filtrates were stored on ice. In parallel, the AAV vector stock was used as a control. Low molecular weight DNA was then isolated from filtrates and retentates and from the 100 ml of non-filtered nuclear fractions and submitted to slot blot analysis. Labeling, hybridization, and quantification were performed, as described above for Southern blotting.
FACS analysis
For FACS analysis, transduced cells were released using 0.05% Trypsin-EDTA (Sigma) for 2 min, followed by incubation for 3 min at 371C. Cells were washed twice with PBS and resupended in FACS buffer (PBS supplemented with 0.5% BSA and 0.1% sodium acid) and were analyzed by flow cytometry in a FACS Calibur (Becton Dickinson, Franklin Lakes, NJ, USA). To assess GFP expression in scAAV2.2-GFP-and scAAV2.6-GFP-transduced cells, the geometric mean of the fluorescence intensity of the entire gated population was measured.
Statistical analysis
To test for statistical significance, Student's t-test was applied. A value of Po0.05 was considered statistically significant.
Abbreviations
AAV, adeno-associated virus; HeLa, tumor cell line; HL-1, cardiac-derived stable cell line; HMEC, human microvascular endothelial cell; PNCMs, primary neonatal rat cardiomyocytes; scAAV2.2, self-complementary AAV2 vector; scAAV2.6, self-complementary pseudotyped AAV2.6 vector
